At the J.P. Morgan Healthcare Conference in San Francisco from January 8 to 11, 2024, \u00a0Ipsen’s management team leaders will discuss our transformation story, next phase of growth and external innovation ambitions.<\/p>\n\n\n\n
Keeping up the growth momentum<\/strong><\/p>\n\n\n\n Over the past three years, we have completely transformed our business and pipeline, delivering on the strategic roadmap established at the end of 2020. We are now ready for the next phase of our transformation.<\/p>\n\n\n\n In full-year 2022, Ipsen passed \u20ac3 billion in total sales. Our portfolio includes four medicines – Dysport, Cabometyx, Decapeptyl as well as Somatuline – each set deliver sales of at least \u20ac500m. In the longer term, we anticipate seven medicines in our portfolio that could reach this potential, positioning us well to sustain attractive growth. <\/p>\n\n\n\n Now, we are gearing for further growth in the period 2023-2027. In December 2023, Ipsen provided a midterm outlook at its Capital Markets Day \u2013 an average total-sales growth of at least 7% per year (at constant exchange rates) and a core operating margin in 2027 of at least 32% of total sales. This outlook excludes the impact of any late-stage external-innovation opportunities.<\/p>\n\n\n\n <\/p>\n\n\n\n Presenting a strong investment case<\/strong><\/p>\n\n\n\n CEO David Loew and CFO Aymeric Le Chatelier are attending the conference, alongside the Investor Relations and Business Development teams. On January 9, David Loew will deliver a presentation on Ipsen\u2019s strategic progress, the mid-term outlook and growth opportunities. His talk will be followed by a Q&A session. We are also organizing a series of meetings to discuss our compelling investment case with investors and analysts. If you are an investor would like to meet our executives and Investor Relations team, we encourage you to contact JP Morgan to arrange a meeting.<\/p>\n\n\n\n <\/p>\n\n\n\n Partnering for life-changing impact<\/strong><\/p>\n\n\n <\/p>\n <\/div>\n\n \n <\/h2>\n